Martingale Asset Management’s Travere Therapeutics TVTX Stock Holding History

Martingale Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$832K	Buy	+14,652	New	+$650K	0.02%	569
2024 Q4	–	Sell	-11,304	Closed	-$158K	–	844
2024 Q3	$158K	Hold	11,304	–	–	﹤0.01%	775
2024 Q2	$92.9K	Buy	+11,304	New	+$76.1K	﹤0.01%	779
2023 Q4	–	Sell	-20,203	Closed	-$181K	–	850
2023 Q3	$181K	Sell	20,203 -24,800	-55%	-$350K	﹤0.01%	755
2023 Q2	$691K	Sell	45,003 -4,700	-9%	-$85.5K	0.01%	536
2023 Q1	$1.12M	Buy	49,703 +200	+0.4%	+$4.25K	0.02%	418
2022 Q4	$1.04M	Buy	49,503 +10,988	+29%	+$233K	0.02%	439
2022 Q3	$950K	Buy	38,515 +23,315	+153%	+$602K	0.02%	456
2022 Q2	$369K	Buy	+15,200	New	+$382K	0.01%	706
2021 Q2	–	Sell	-18,615	Closed	-$465K	–	899
2021 Q1	$465K	Sell	18,615 -1,400	-7%	-$38.7K	0.01%	628
2020 Q4	$547K	Sell	20,015 -75,800	-79%	-$1.77M	0.01%	592
2020 Q3	$1.77M	Sell	95,815 -95,500	-50%	-$1.86M	0.02%	454
2020 Q2	$3.91M	Buy	+191,315	New	+$3.05M	0.05%	364

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Martingale Asset Management's TVTX Position: Q2 2026 in Review

Martingale Asset Management opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 14,652 shares worth $832K. The stake represents 0.02% of the portfolio and ranks #569 among its holdings. This is a return to the name: Martingale Asset Management previously reported a position in TVTX as recently as Q3 2024.

Martingale Asset Management first reported a position in TVTX in Q2 2020 and has held it in 13 quarters since. The position peaked at $3.91M in Q2 2020. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Martingale Asset Management held 14,652 shares of Travere Therapeutics worth $832K as of Q2 2026.
Travere Therapeutics was a new Martingale Asset Management position in Q2 2026.
Travere Therapeutics made up 0.02% of Martingale Asset Management's portfolio in Q2 2026, its #569 holding.
Martingale Asset Management first reported a position in Travere Therapeutics in Q2 2020 and has held it in 13 quarters since.
Martingale Asset Management's Travere Therapeutics position peaked at $3.91M in Q2 2020.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.